FAM161 centrosomal protein BGenealiases: C14orf44 · c14_5547
Q-omics provides the consensus-scored FAM161B profile across patient tissues and cancer cell-line models. FAM161B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, FAM161B is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, FAM161B RNA expression shows 21,644 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KICH, COAD, and PDAC as cancer lineages where FAM161B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM161B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM161B survival associations across molecular data types. FAM161B RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM161B RNA expression–survival associations across cancer types. High FAM161B expression shows unfavorable associations in KICH, ACC and STAD, but favorable associations in KIRC, BRCA and UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for FAM161B RNA expression.
This table summarizes FAM161B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for FAM161B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM161B shows lower tumor expression in COAD, THCA, KICH, UCEC and KIRC and higher tumor expression in LIHC. The COAD box plot shows higher FAM161B RNA expression in normal versus tumor tissue (log2 FC = −1.076, t-test p < 0.001).
This table shows molecular features associated with FAM161B in patient tissues and cancer cell lines. In patient samples, FAM161B shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM161B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_NSCLC_LUAD.
